BackPhio Pharmaceuticals - Warrants (21/12/2021) Overview

Phio Pharmaceuticals - Warrants (21/12/2021) Current Cash

Phio Pharmaceuticals - Warrants (21/12/2021)'s current cash is $17M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$17.03M
28.26% YoYΔ $3.75M vs prior year quarter

Peer average

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) Current Cash History

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) vs. peers: Current Cash Comparison

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Phio Pharmaceuticals - Warrants (21/12/2021) (PHIOW) FAQ

As of the most recent data (March 2026), PHIOW shows a current cash of $17M. That compares with $13M in the prior-year period — up 28.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHIOW's current cash is now $17M (was $13M) — a 28.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Phio Pharmaceuticals - Warrants (21/12/2021) is outperforming or lagging.

Tracking PHIOW's current cash over time shows whether Phio Pharmaceuticals - Warrants (21/12/2021) is scaling, shrinking, or reshaping that part of the business. The current reading is $17M That compares with $13M in the prior-year period — up 28.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Phio Pharmaceuticals - Warrants (21/12/2021)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $17M) with ownership activity and broader fundamentals.

Phio Pharmaceuticals - Warrants (21/12/2021)'s current cash is $17M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.